Visen Pharmaceuticals is an innovative biopharmaceutical company that specializes in endocrine-related treatments. The company is dedicated to improving the treatment process and outcomes for patients with endocrine disorders, with a focus on providing innovative therapies that are more humane and patient-centered.

Visen's primary product is a growth hormone injection, known as SKYTROFA®, which has been approved by the U.S. Food and Drug Administration (FDA) for use in children over one year old, weighing at least 11.5 kg, who have growth disorders due to insufficient secretion of endogenous growth hormone. This is the first FDA-approved product that can continuously release growth hormones for a week with just one injection.

In addition to this, Visen is also conducting clinical research on hypoparathyroidism, a condition where the body produces insufficient parathyroid hormone, leading to low calcium levels in the blood. The company has received approval from the China National Medical Products Administration (NMPA) for phase III clinical trials of TransCon PTH injection, a potential hormone replacement therapy aimed at normalizing blood calcium levels while discontinuing conventional treatment.

Visen operates in the pharmaceutical market, serving clients such as hospitals, clinics, and patients who require endocrine-related treatments. The company makes money by developing, manufacturing, and selling pharmaceutical products. It also collaborates with research institutions, like the Peking University Clinical Research Institute, to further its research and development efforts.

Keywords: Biopharmaceutical, Endocrine Treatments, Growth Hormone Injection, SKYTROFA®, FDA Approval, Hypoparathyroidism, TransCon PTH Injection, Clinical Research, Pharmaceutical Market, Research Collaboration.